Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i got the shares at 35 :))
currently bid 0.25
ask 50...
what happens if price goes above 50
http://www.lowfloat.com/all_with_otcbb/
Ticker Company Exchange Float Outstd ShortInt Industry
LGYV Legacy Ventures International OTCBB 28K 315K N/A Real Estate Operations
PRLE Paragon R.E. Equity & Invest OTCBB 67K 405K N/A Misc. Financial Services
PIAC Princeton Capital Corp OTCBB 75K 120.49M N/A Misc. Financial Services
HKNI HKN, Inc. OTCBB 102K 391K N/A Chemical Manufacturing
SECI SECTOR 10 Inc OTCBB 132K 306K N/A Security Systems & Services
EACO EACO Corp OTCBB 155K 4.86M N/A Electronic Instruments & Controls
SECI is number 5 of all low float stocks
but SECI has possible billion dollar judgment
ridesharing LYFT UBER
what about HYRE
same OS
not much revenue
trading above 5 dollars
what is the float
is it 23.5M or less than 144000
from 600K registered users to 11M...
now that 11M will even expand
word of mouth I guess
this is like FB in its infancy... you upload pics, you checked in... you answer survey questions... etc... but you earn points and money
so, any good news... will Trov jump
some marijuana CBD stocks have market values of more than 100m
even at $2... IGNG with 40M OS is stil below 100M
As previously announced, on Thursday, March 7, GBI obtained its final permit and clearance from the Desert Hot Springs fire department to commence operation of an ethanol-based extraction laboratory at its facilities. As an update to the previous announcement, GBI intends to commence extraction operations the week of March 25, 2019.
i found something... even bigger 14B
https://www.thedrum.com/news/2018/06/27/indy-network-local-planet-restructures-global-stand-against-the-holding-groups
The group, built on the power of a local touch in marcomms, will look to attract clients with an emphasis on transparency, backed by a zero-rebate policy and a full disclosure of fees and margins. Just two years after being founded, the group boasts 51 agencies in 68 markets worldwide, with combined client media billings of more than $14bn.
Rattle said: “When we launched Local Planet two years ago, our vision was to create a genuine alternative to the global holding company media agency networks by offering international clients all the benefits of a global network but with the spirit, drive and focus of an entrepreneurial business, prioritising client outcomes, rather than external shareholder demands.
“This new structure ensures that our international clients can feel even more confident in the quality and consistency of service that we can provide to them across multiple markets around the world.
“Our international clients are increasingly those who feel that they have not been prioritised by the large media holding groups and who are looking for an entrepreneurial, nimble and transparent agency partner. These clients deserve the best talent working on their business, irrespective of their size.
Fletcher added: “Independent media thinking and the freedom to operate transparently for clients is a compelling offering and one we believe that all clients deserve. Many of them are aware that as an industry, we have sleepwalked into the 21st century with 20th-century business models, practices and thinking. The interest in Local Planet is because we are offering a genuinely alternative approach.”
Among its agency shareholders are Horizon Media, The7stars, Goodstuff, CoSpirit MediaTrack, Zertem Communications Group, Pilot, Media Italy, Tre Kronor, The Media Shop, Blue Focus Communications Group, Effective Media, Mediaxplain and Ignis Media.
(LPI) GLOBAL MEDIA AGENCY NETWORK. The world’s largest independent Media Agency Network. A union of the fastest growing and most celebrated independent media agencies on the planet. LPI with 51 of the world's best in class, fastest growing, independent media agencies in 67 market worldwide. Global Media revenues billings of $15.75 billion.
other than the newsletter... are there any other sources or links to confirm this 15.75B
15.75B x 0.05 / 1.6B shares = 0.5 ... thats just Local Planet alone
lets see if this will go BPTH move
on the 4th day,,, BPTH went to 73
today is ATOS 4th day
if u guys noticed... BPTH did same thing too..
it went up to 7.69
then dropped to 4.38
and on the 4th day... 73.52
Date Open High Low Close* Adj Close** Volume
Mar 15, 2019 27.50 31.99 27.49 30.10 30.10 1,403,507
Mar 14, 2019 28.11 30.86 27.00 27.47 27.47 1,750,600
Mar 13, 2019 35.34 36.25 31.02 31.05 31.05 2,495,200
Mar 12, 2019 30.78 39.88 28.15 35.13 35.13 11,140,600
Mar 11, 2019 22.98 38.00 22.00 32.44 32.44 11,674,500
Mar 08, 2019 33.85 35.86 21.00 21.00 21.00 5,340,000
Mar 07, 2019 18.20 73.52 17.01 38.86 38.86 36,079,200
Mar 06, 2019 7.45 14.60 6.91 12.02 12.02 72,385,800
Mar 05, 2019 5.20 5.23 4.38 4.62 4.62 1,951,100
Mar 04, 2019 6.80 7.69 5.40 5.50 5.50 7,718,200
Mar 01, 2019 2.65 8.84 2.65 7.72 7.72 58,812,200
Feb 28, 2019 2.00 2.73 1.98 2.60 2.60 1,291,800
TNXP
another one
1.5M OS
500K floay
another possible BPTH like ATOS
the results for 3 months and then 6 months are forthcoming... topical endoxifen
Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density
PDF version Printer Friendly
SEATTLE, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, has completed enrollment in its Phase 2 study of Atossa's proprietary Topical Endoxifen in women with mammographic breast density, or MBD.
This double-blinded, placebo-controlled Phase 2 study is being conducted at Stockholm South General Hospital in Sweden. The study is being led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. "We are very pleased with the speed at which the study has fully enrolled 90 participants in under 6 weeks," commented Dr. Hall. "This fast enrollment is a testament to the hard work and superlative service of my dedicated staff and the positive experience patients have had with this novel topical drug," continued Dr. Hall.
Steve Quay, MD, Ph.D., CEO and President of Atossa, commented, "We are thrilled with Dr. Hall's and his team's work on our lead Endoxifen program and the rapid progress at his clinic. Quick enrollment in clinical trials can be a good indicator that there is strong demand for a therapy in an underserved market."
The primary endpoint of the study is to determine if daily Topical Endoxifen administration results in an individual change in MBD, which will be measured after three and six months of entering the study. The secondary endpoints are safety and tolerability. Ninety participants were randomized to one of three groups (one placebo group and two groups of different strengths of Topical Endoxifen) with 30 participants per group. The objective of the study is to determine if MBD is reduced, and if so, the results will drive sample size calculations for a future a Phase 3 study.
this was the BPTH move... it moved from 2+ to 74 after 5 days
hmmmm
Date Open High Low Close* Adj Close** Volume
Mar 14, 2019 28.11 30.86 27.50 28.83 28.83 713,350
Mar 13, 2019 35.34 36.25 31.02 31.05 31.05 2,489,100
Mar 12, 2019 30.78 39.88 28.15 35.13 35.13 11,140,600
Mar 11, 2019 22.98 38.00 22.00 32.44 32.44 11,674,500
Mar 08, 2019 33.85 35.86 21.00 21.00 21.00 5,340,000
Mar 07, 2019 18.20 73.52 17.01 38.86 38.86 36,079,200
Mar 06, 2019 7.45 14.60 6.91 12.02 12.02 72,385,800
Mar 05, 2019 5.20 5.23 4.38 4.62 4.62 1,951,100
Mar 04, 2019 6.80 7.69 5.40 5.50 5.50 7,718,200
Mar 01, 2019 2.65 8.84 2.65 7.72 7.72 58,812,200
Feb 28, 2019 2.00 2.73 1.98 2.60 2.60 1,291,800
maybe this will do an BPTH move
will see
low OS low float
worked presurgery.... currently post surgery
if this works... to the moon
maybe fast track
ALQA + Adynxx = new ADYNXX with new symbol
Aquamed + TO = TO PHARMA, to go public
+ dividends
http://www.nashbiotechs.com/nash-biotech-analysis/biotechs-targeting-nash/detailledList.php
NP160 (NP160), Laboratory : NashPharmaceuticals
Type of drug : ??
Clinical trials advancement : Preclinic
The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3
Estimated Time to market in months : 105
NP135 (NP135), Laboratory : NashPharmaceuticals
Type of drug : ??
Clinical trials advancement : Preclinic
The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3
Estimated Time to market in months : 106